Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus
Gjin Ndrepepa, Adnan Kastrati, Maurizio Menichelli, Franz-Josef Neumann, Jochen Wöhrle, Isabell Bernlochner, Gert Richardt, Bernhard Witzenbichler, Dirk Sibbing, Senta Gewalt, Dominick J. Angiolillo, Christian W. Hamm, Alexander Hapfelmeier, Dietmar Trenk, Karl-Ludwig Laugwitz, Heribert Schunkert, Stefanie Schüpke and Katharina Mayer
Efficacy Endpoints With Ticagrelor and Prasugrel in Patients With and Without Diabetes
(Left) One-year cumulative incidence of the primary endpoint (1-year incidence of death, myocardial infarction, or stroke) in patients with or without diabetes mellitus (DM) assigned to prasugrel or ticagrelor. (Right) Treatment effect and interaction associated with ticagrelor or prasugrel in patients with and without DM. Hazard ratios along with 95% confidence intervals (CIs) for the individual endpoints (right) are shown in Table 2.